There is significant variability in infliximab (IFX) pharmacokinetics (PK) in children and adults with multiple population PK models developed and several covariates identified to better predict drug clearance. Fortunately, therapeutic drug monitoring (TDM) is widely available and can be used to simplify model-informed precision dosing. However, empiric (“trial and error”) dose intensifications following TDM to achieve targeted levels can delay obtaining an optimal drug exposure and is a risk for super-therapeutic levels.